New drug combination for the second treatment of some HR-positive advanced breast cancers
Full article:

The FDA approved Truqap plus Faslodex for the treatment of metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer that returned or worsened after treatment with hormone therapy. The approval is for treating cancers in people whose tumors had a mutation in one of three genes. For people with one of these mutations, Truqap improved the time until their cancer came back or got worse.  (Posted 2/9/24)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following organizations have resources related to breast cancer. 

The National Comprehensive Cancer Network (NCCN) indicates that tumor testing can help determine if a person with metastatic breast cancer would benefit from targeted therapy.

The following are studies looking at treatment for people with metastatic HER2-positive breast cancer.  

Other clinical trials for people with breast cancer can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.